Wellesley, MA, United States of America

Arthur Mertz Krieg

USPTO Granted Patents = 68 

 

 

Average Co-Inventor Count = 2.5

ph-index = 30

Forward Citations = 4,173(Granted Patents)


Inventors with similar research interests:


Location History:

  • Wellesely, MA (US) (2004)
  • Iowa City, IA (US) (2001 - 2011)
  • Wellesley, MA (US) (2007 - 2014)
  • Cambridge, MA (US) (2015 - 2023)

Company Filing History:


Years Active: 2001-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Tumor Immunotherapy
RIG-I-Like Receptor Agonists
MECP2 Expression Modulation
Multimeric Oligonucleotide Compounds
Amyotrophic Lateral Sclerosis
Hemoglobin Gene Family Expression
Immunomodulatory Oligonucleotides
Immunostimulatory Nucleic Acids
Nucleic Acid Compositions
CpG Nucleic Acids
Nucleic Acid-Lipophilic Conjugates
Infectious Disease Prevention
68 patents (USPTO):Explore Patents

Title: Arthur Mertz Krieg: Innovator in RNA Therapeutics

Introduction

Arthur Mertz Krieg, based in Wellesley, MA, is a distinguished inventor holding an impressive portfolio of 66 patents. His pioneering work primarily focuses on biotechnological advancements, particularly in the fields of RNA therapeutics and gene expression modulation.

Latest Patents

Among his latest contributions are critical inventions relating to MECP2 expression modulation. One of his patents outlines compositions and methods for enhancing the expression of MECP2 through single-stranded oligonucleotides. These innovations not only include compositions and kits designed to activate MECP2 expression but also offer methods for selecting candidate oligonucleotides. Furthermore, he has developed synthetic RIG-I-like receptor agonists aimed at treating disorders such as cancer by utilizing RNA molecules that effectively engage RIG-I-like receptors.

Career Highlights

Throughout his career, Krieg has made significant strides in research and therapeutic development. He has been affiliated with the University of Iowa Research Foundation, where his expansive research laid the groundwork for many of his patents. Additionally, his time at Coley Pharmaceutical Group, Inc. has further propelled his innovations in the pharmaceutical landscape.

Collaborations

Arthur Mertz Krieg has collaborated with notable researchers in the field, including Dennis M Klinman and Alfred D Steinberg. These partnerships have contributed to the development of groundbreaking technologies that continue to influence therapeutic approaches in modern medicine.

Conclusion

Arthur Mertz Krieg stands out as a prominent figure in biotechnology, exemplified by his extensive patent portfolio and impactful research contributions. Through his innovative approaches to RNA therapies and gene expression modulation, he has set a high standard for future developments in the biopharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…